Track topics on Twitter Track topics that are important to you
Latokartanonkaari 11 D-talo
Phone: 358- 9- 3478 900
Fax: 358-9- 3478 9090
Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheime...
Now that scientists agree that oligomer protein deposits cause Alzheimer's, an international team has detailed a plan for developing drugs to target them.
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer TORONTO and CAMBRIDGE, Mass., Nov. 06, 2018 In this presentati...
The formation of amyloid-β peptide (Aβ) oligomers at the cellular membrane is considered a crucial process that underlies neurotoxicity in Alzheimer's disease (AD). To obtain structural information ...
This study describes a novel electrochemical aptasensor for detection of α-synuclein (α-syn) oligomer, an important biomarker related to Parkinson's and Alzheimer's diseases. The sensing platform is...
The effects of oligomer length, solvent, and temperature on the self-association of stably folded short aromatic oligoamide are probed. With large flat surfaces, these aromatic oligoamides undergo sta...
A study of reaction kinetics and removal efficiency of a family of ruthenium (Ru)-based olefin metathesis catalysts containing ethylene-glycol-oligomer-tethered N-heterocyclic carbene (NHC) ligands ha...
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease characterized by motor neuron loss in the brain and spinal cord. Mutations in Cu-Zn superoxide dismutase (SOD1) a...
This is a multi‐center, Phase 1b, randomized, double‐blind, placebo‐controlled parallel‐group trial in adults with mild to moderate AD.
AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease. AVI-4065...
Duchenne muscular dystrophy (DMD), a fatal muscle degenerative disorder, arises from mutations in the dystrophin gene. Antisense therapy with the use of antisense oligonucleotides (AON) ha...
Bio-Synthesis Inc was the first commercial company providing DNA and peptides in 1984. We specialize in custom peptide synthesis from small to large scale and we can help you design the optimal pepti...
PolyMedix is the leader in developing biomimetics - novel small molecule, oligomer and polymer protein-mimetic drugs for membrane protein and protein:protein targets. PolyMedix has a proven computatio...
Established in 1990, BioChrom Labs, Inc., Indiana, USA, is dedicated to developing and manufacturing polymeric materials using patentable and proprietary technologies. HYDROCELL HPLC Columns and packi...
Innovative RNA-Based Technology; First-in-Class Therapeutics Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to imp...
We have published hundreds of Oligomer Oy news stories on BioPortfolio along with dozens of Oligomer Oy Clinical Trials and PubMed Articles about Oligomer Oy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oligomer Oy Companies in our database. You can also find out about relevant Oligomer Oy Drugs and Medications on this site too.